Biofrontera AG (BFRA)
BFRA Price and Sentiment
BFRA Latest news
Biofrontera AG receives FDA-approval of the BF-RhodoLED® XL lamp
2021-10-22 09:55Leverkusen, Germany, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced the approval of the new red-light source for photodynamic therapy (PDT), the BF-RhodoLED® XL, by the U.S. Food and Drug Administration (FDA). In accordance with FDA requirements, the approval was granted as a combination approval with our prescription drug Ameluz®, same as the approval with the predecessor model BF-RhodoLED®.
Biofrontera reports preliminary approximate revenues for the month of September 2021
2021-10-01 07:44Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021.
Biofrontera reports preliminary revenue for the month of August 2021
2021-09-08 12:10Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021.
Biofrontera AG's (BFRA) CEO Hermann Lübbert on Q2 2021 Results - Earnings Call Transcript
2021-08-20 12:44Biofrontera AG's (BFRA) CEO Hermann Lübbert on Q2 2021 Results - Earnings Call Transcript
Biofrontera reports financial results for the six months ended June 30, 2021
2021-08-19 11:47Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021.
Biofrontera AG: Conference call to discuss half-year 2021 financial results to be held on August 20, 2021
2021-08-12 08:55Leverkusen, Germany, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its financial results for the first six months ended June 30, 2021 on Thursday, August 19, 2021.
Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland
2021-07-23 04:15Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland.
Biofrontera Inc.: U.S. Subsidiary Of German Dermatology Company Files S-1
2021-07-13 14:21Biofrontera Inc. is presently a wholly owned U.S. subsidiary of Biofrontera AG (BFRA).
Biofrontera Inc. seeks IPO in the USA
2021-07-06 17:59Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc.